Form 4: Immunome CSO Jack Higgins Granted 196,000 Stock Options

Immunome Inc.'s Chief Scientific Officer, Jack Higgins, was granted 196,000 employee stock options with an exercise price of $10.6, vesting over several years.

Summary

• Immunome Inc. (IMNM) Chief Scientific Officer, Jack Higgins, was granted 196,000 employee stock options.
• The options have an exercise price of $10.6 per share.
• The grant date for these options was July 29, 2025.
• 25% of the shares subject to the options will vest on July 29, 2026.
• One-thirty-sixth (1/36th) of the remaining shares will vest every month thereafter.
• The options are set to expire on July 28, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is a positive development for aligning management incentives with long-term shareholder value, reflecting a commitment to the company's future. It is a routine compensation event, hence a moderately positive score.

Positives

• The grant of stock options to a key executive like the Chief Scientific Officer aligns management's long-term interests with those of shareholders, incentivizing performance and value creation.

Future Outlook

The vesting schedule for the granted options extends over several years, indicating a long-term incentive structure for the Chief Scientific Officer, aligning their future performance with the company's long-term success.

Industry Context

Granting stock options to key executives is a common practice in the biotechnology and pharmaceutical industries. This compensation method is widely used to attract, retain, and incentivize top talent by linking their financial success directly to the company's stock performance and long-term value creation.

Comparison to Industry Standards

• Granting stock options to key executives like a Chief Scientific Officer is a standard component of compensation packages across the biotechnology sector.
• The specific size of the grant (196,000 options) and the exercise price ($10.6) would typically be evaluated against peer companies' executive compensation structures and the company's market capitalization and stage of development, though such comparative data is not provided in this filing.

Related Party Transactions

• Grant of 196,000 employee stock options to Chief Scientific Officer Jack Higgins, a related party.

Stakeholder Impact

• Shareholders: Potential for increased alignment of executive interests with long-term shareholder value through performance-based incentives.
• Employees: Reflects standard executive compensation practices within the company.

Next Steps

• The Chief Scientific Officer must remain employed and meet the specified vesting conditions to fully realize the value of the granted options.
• Future Form 4 filings will report any exercise or sale of these options.

Key Dates

Recommendation

This filing reports a routine grant of stock options to a key executive, which is a standard compensation practice. While it aligns management incentives with long-term shareholder value, it does not provide new fundamental information or significant operational updates that would warrant a change in an investment thesis. Therefore, a 'hold' recommendation is appropriate based solely on the content of this specific filing.

Keywords

Immunome, IMNM, Stock Option, Employee Stock Option, Executive Compensation, Jack Higgins, Chief Scientific Officer, CSO, Equity Grant, Insider Transaction